【摘要】 狼疮性肾炎(LN)是系统性红斑狼疮(SLE)最严重的靶器官损害，也是SLE患者发病和死亡的重要原因。LN发病机制主要与多因素导致免疫系统的过度激活及免疫复合物的清除障碍相关。作为LN诊断的金标准，肾活检有创且价格昂贵，部分医疗机构尚未开展，新型生物标志物的发现为LN早期诊断、疗效监测及预后评估提供了新的方法。医学的不断进步不仅推动了生物制剂的发展，也为传统治疗药物提供了新的视角，实现老药新用。目前，LN发病机制不断被深化，其诊断和治疗也正朝着更加精准、无创、个体化的方向发展，随着靶向药物的不断研发，多种生物制剂的上市也为LN的治疗提供了新选择，LN患者生存率已较之前显著提高。然而对于新型药物长期使用的有效性及安全性仍需进一步临床研究。更多还原

【Abstract】 Lupus nephritis(LN) is the most serious target organ damage in systemic lupus erythematosus(SLE), and it is also an important cause of morbidity and mortality in SLE patients. The pathogenesis of LN is mainly related to the excessive activation of the immune system and the clearance of immune complexes caused by multiple factors. As the gold standard for the diagnosis of LN, renal biopsy is invasive and expensive, and some medical institutions have not yet conducted it. The discovery of new biomarkers provides a new method for early diagnosis, efficacy monitoring, and prognosis evaluation of LN. The continuous progress of medicine not only promotes the development of biologics, but also provides new perspectives for traditional therapeutic drugs, realizing the new use of old drugs. At present, the pathogenesis of LN is constantly deepening, and its diagnosis and treatment are also developing towards more precise, non-invasive, and personalized directions. With the continuous development of targeted drugs and the launch of various biological preparations, new options for the treatment of LN have been provided, and the survival rate of LN patients has significantly improved than before. However, further clinical studies are still needed on the efficacy and safety of the long-term use of new drugs.更多还原